SARS-CoV recombinant vaccine (Novavax)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameSARS-CoV recombinant vaccine (Novavax)
Drug Alias NameSARS vaccine (Novavax)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovavax Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovavax Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksN/A